tosovap
Tolvaptan is a selective vasopressin V2-receptor antagonist to slow kidney function decline in patients at risk for rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). Also used to treat hypervolemic and euvolemic hyponatremia associated with various conditions like congestive heart failure, cirrhosis, and syndrome of inappropriate antidiuretic hormones (SIADH).
Composition:
Tolvaptan IP 15 mg Tablets
Mode of Action
Tolvaptan is a selective vasopressin V 2 receptor antagonist and the first and only drug approved for treatment of ADPKD. Tolvaptan blocks binding of arginine vasopressin (AVP) to V 2 receptors in the collecting duct of kidney, thereby inducing water diuresis (aquaresis) without losing electrolytes. Cyclic adenosine monophosphate (cAMP) plays an important role in cyst growth by promoting cell proliferation and fluid secretion. Tolvaptan showed suppression of cyst growth through inhibiting AVP-induced cAMP production and delayed the onset of end-stage renal disease.
Indications
For ADPKD (Autosomal Dominant Polycystic Kidney Disease)- a genetic disease characterized by the development of multiple, non-malignant cysts in kidneys, which leads to complications including chronic and acute pain, hypertension and kidney failure, For hyponatremia (low levels of sodium in the blood) in people with heart failure, liver disease, and syndrome of inappropriate antidiuretic hormone (SIADH). Tolvaptan improves urine flow without causing the body to lose too much sodium in urine.
Dosage
Initiate at 45 mg (morning) plus 15 mg (evening) daily. Titrate every 1–4 weeks to 90 mg (morning) plus 30 mg (evening) daily or maximum tolerated dose.
This information is for the registered medical practitioners only. Consult your medical practitioner before consuming the products.